Compare LARK & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LARK | TLSA |
|---|---|---|
| Founded | 1885 | 2013 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 167.8M | 182.7M |
| IPO Year | N/A | 2000 |
| Metric | LARK | TLSA |
|---|---|---|
| Price | $25.64 | $1.52 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 9.3K | ★ 372.2K |
| Earning Date | 02-03-2026 | 05-06-2025 |
| Dividend Yield | ★ 3.22% | N/A |
| EPS Growth | ★ 38.73 | N/A |
| EPS | ★ 2.84 | N/A |
| Revenue | ★ $64,367,999.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $8.80 | ★ N/A |
| Revenue Growth | ★ 12.95 | N/A |
| 52 Week Low | $20.99 | $0.63 |
| 52 Week High | $29.56 | $2.60 |
| Indicator | LARK | TLSA |
|---|---|---|
| Relative Strength Index (RSI) | 24.40 | 44.96 |
| Support Level | $24.85 | $1.44 |
| Resistance Level | $26.03 | $1.61 |
| Average True Range (ATR) | 0.70 | 0.13 |
| MACD | -0.40 | 0.01 |
| Stochastic Oscillator | 4.90 | 61.89 |
Landmark Bancorp Inc is the bank holding company for Landmark National Bank, which is dedicated to providing quality financial and banking services. The Bank has continued to focus on increasing its originations of commercial, commercial real estate (CRE), and agricultural loans, which management believes will be more profitable and provide more growth for the Bank than traditional one-to-four-family residential real estate lending. In addition, it also invests in certain investment and mortgage-related securities using deposits and other borrowings as funding sources. Its primary deposit gathering and lending markets are geographically diversified with locations in central, eastern, southeast, and southwest Kansas.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease, and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.